VANCOUVER, BC, September 7, 2022 /CNW/ – Nirvana Life Sciences Inc. (Nirvana or the “Company”) (CSE: NIRV)a Western Canada-based life sciences company that aims to develop psychedelic therapeutic drugs, including drugs and pharmaceutical formulations that prevent chronic pain and non-addictive relapses, is pleased to announce the development of a more efficient way to produce MDMA.
Nirvana Life Sciences Inc. is pleased to announce the development of a new method of producing MDMA (3,4-methylenedioxy methamphetamine) that dramatically reduces manufacturing time. This 3-step synthesis, starting from the precursor safrole, takes only 24 hours, depending on the method of reduction of the ketone to secondary amine used. This is about a third of the time required to complete current production methods using iso-safrole as an intermediate. Nirvana has filed an application with the United States Patent Office for this invention.
MDMA was first synthesized in 1912, but its therapeutic potential has only recently been investigated. The drug is a potent central nervous system (CNS) stimulant whose effect varies widely from other common stimulants found in the same family of phenethylamine compounds. It is currently being studied and used for the treatment of a wide range of psychiatric disorders such as post-traumatic stress disorder (PTSD), depression and anxiety to name a few. MDMA-assisted psychotherapy is currently in phase three clinical trials for the treatment of PTSD in the United States, Canada and Israel. This year, the FDA expanded access to MDMA, allowing its compassionate use in clinical settings by patients who have not had success with other FDA-approved treatment options.
MDMA effectively shuts down the brain’s fight-or-flight response and creates a sense of empathy in patients, allowing them to process trauma more effectively. Drugs increases the amount of serotonin in the synaptic clefts of serotonergic neurons. It also binds to various serotonin receptors and overactivates them, while simultaneously reducing the reuptake of other neurotransmitters, which is the primary mechanism of drug action.
Chief Chemist and Head of Innovation for Nirvana Life Sciences Inc., Robert August, was one of the first researchers to successfully crystallize MDMA HCl monohydrate, a new form of MDMA with increased bioavailability and efficacy. The synthesis method he developed can also be seamlessly integrated into the production of MDMA HCl Monohydrate, which Nirvana Life Sciences Inc. recently announced a patent pending for. With the renewed interest in MDMA research growing in recent years and the growing potential for its use in therapeutic settings, Nirvana believes this breakthrough is a significant step forward in the emerging psychedelic drug space.
Mr. Robert August said, “As a chemist working hard to advance the field of pharmaceutical psychedelics with new and improved therapeutic drugs and their manufacturing methods, advancing this synthetic route and the monohydrate variant for research is an important development. Not only this will save time and money in the production of MDMA, but it also works well with the crystallization of MDMA as the monohydrate.I hope this breakthrough will break down some of the barriers in production, research and the effective therapeutic use of these compounds.
About Nirvana Life Sciences Inc.
Nirvana Life Sciences Inc. was founded with a simple goal of researching and developing non-addictive pain management and relapse prevention products that alleviate symptoms of chronic pain and support patients struggling with addiction. Nirvana believes the combination of naturally occurring psychedelics with modern medicine holds promise for providing non-addictive therapeutic solutions. Supported by a team of world-renowned researchers, Nirvana will develop life-changing therapies for those suffering from pain and addiction and, in turn, alleviate the financially strained medical system.
This press release contains certain forward-looking statements and information (collectively referred to herein as forward-looking statements) within the meaning of Canadian securities laws, including, without limitation, statements regarding the Company’s future investments. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements do not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions upon which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on any forward-looking statements included herein, as there can be no assurance that the plans, intentions or expectations on which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results of the Company in future periods differ materially from any estimate or projection of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and the Company undertakes no obligation to publicly update or revise any of the forward-looking statements included, except as required by applicable law. The front-the forward-looking statements contained herein are expressly qualified by this cautionary statement.
SOURCENirvana Life Sciences Inc.
Show original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2022/07/c2284.html